Table 1 Patient characteristics
Total cohort | Matched cohort | ||
|---|---|---|---|
Benepali® | Benepali® | Enbrel® | |
n=83 | n=71 | ||
Female, n (%) | 60 (72.3%) | 51 (71.8%) | 52 (73.2%) |
Age at JIA onset, mean (SD), median | 8.8 (4.7), 9.4 | 8.7 (4.6), 9.8 | 8.7 (4.6), 9.8 |
sJIA, n (%) | 3 (3.6%) | 3 (4.2%) | 3 (4.2%) |
RF negative PA, n (%) | 22 (26.5%) | 19 (26.7%) | 19 (26.7%) |
RF positive PA, n (%) | 9 (10.8%) | 7 (9.9%) | 7 (9.9%) |
Enthesitis-related arthritis, n (%) | 17 (20.5%) | 16 (22.5%) | 15 (21.1%) |
Psoriatic arthritis, n (%) | 4 (4.8%) | 4 (5.6%) | 4 (5.6%) |
Other arthritis, n (%) | 5 (6.0%) | 5 (7.0%) | 5 (7.0%) |
Oligoarthritis, persistent, n (%) | 4 (4.8%) | 2 (2.8%) | 2 (2.8%) |
Oligoarthritis, extended, n (%) | 19 (22.9%) | 15 (21.1%) | 16 (22.5%) |
ANA positive, n (%) | 31 (37.8%) | 26 (36.6%) | 27 (28.0%) |
HLA B27 positive, n (%) | 27 (32.9%) | 24 (33.8%) | 23 (32.4%) |
Uveitis/history, n (%) | 2 (3.8%) | 1 (2.1%) | 1 (2.1%) |
Disease duration at start of treatment with Benepali®, years, mean (SD), median | 13.8 (6.2), 13.7 | 13.6 (5.9), 13.1 | 6.1 (7.4), 7.1 |
Age at start of treatment with Benepali®, mean (SD), median | 22.5 (4.4), 21.3 | 22.1 (4.3), 21.2 | 14.7 (6.1), 15.3 |